Skip to main content
EVMN logo

Evommune, Inc.

EVMNNYSEHealthcareBiotechnology

$5.17Today:- (-)

As of Oct 16, 2026 close

Market cap
$214.28M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.64$33.20
Volume (live)
-
Avg. volume (3M)
924.80K

Evommune (EVMN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Evommune used $76.44M of cash in operating activities and spent $235.00K on capital expenditures. That left free cash flow of −$76.68M. It repurchased $1.22M of its own shares.

Evommune Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Evommune, Inc. (EVMN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023
Period endingDec 2025Dec 2024Dec 2023
Operating Activities
Net Income-68.87-66.81-34.05
Depreciation & Amortization1.391.291.00
Stock Based Compensation5.860.000.00
Change in Working Capital-4.127.423.34
Change in Accounts Payable-0.846.510.13
Change in Other Working Capital-3.100.923.22
Other Operating Activities-10.70-0.10-0.26
Net Cash from Operating Activities-76.44-58.20-29.97
Investing Activities
Capital Expenditures-0.24-0.09-0.12
Purchases of Investments-115.07-90.26-91.31
Sales/Maturities of Investments84.1086.3543.00
Net Cash from Investing Activities-115.31-3.99-48.43
Financing Activities
Debt Repayment-0.370.000.00
Common Stock Issued157.2949.8463.98
Common Stock Repurchased-1.220.000.00
Other Financing Activities-1.76-0.42-0.23
Net Cash from Financing Activities220.7649.4263.75
Summary
Effect of Forex Changes on Cash-1.210.0043.67
Net Change in Cash29.02-12.7729.02
Cash at Beginning of Period16.2529.020.00
Cash at End of Period44.0616.2529.02
Free Cash Flow-76.68-58.28-30.09
Supplemental Disclosures
Interest Paid0.010.030.06

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evommune Cash Flow

What is Evommune's free cash flow?

Evommune had negative free cash flow of $76.68M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$76.44M minus $235.00K of capital expenditures.

How much does Evommune spend on capital expenditures?

Evommune spent $235.00K on capital expenditures in fiscal 2025, compared with $88.00K a year earlier.

Does Evommune pay dividends or buy back shares?

Yes. In fiscal 2025 Evommune returned $1.22M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition